Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

143
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
143
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

26
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
26
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

28
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
28
Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

1.4K
Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
1.4K
Gastritis III: Clinical Manifestations and Management01:23

Gastritis III: Clinical Manifestations and Management

604
The clinical manifestations of gastritis can vary depending on the cause and type of gastritis, but some common symptoms may include the following.
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
604
Esophageal Varices-II: Clinical Features and Management01:28

Esophageal Varices-II: Clinical Features and Management

179
Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
179

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Corrigendum to 'Eco-friendly approach for the removal and simultaneous detection of cyanide toxins from drinking and wastewater sources' [Environ. Pollut. 385 (2025) 127094].

Environmental pollution (Barking, Essex : 1987)·2026
Same author

Efficacy and safety of antegrade ureteroscopic lithotripsy versus retrograde ureteroscopic lithotripsy in the treatment of upper ureteric stones measuring > 10 mm in maximum dimension and/or impacted stones: randomized comparative study.

World journal of urology·2026
Same author

The diagnosis and management of portal hypertension in cirrhosis: The Gastroenterological Society of Australia consensus.

Hepatology communications·2026
Same author

The FAITH (Flinders Albumin in the Home) study.

Internal medicine journal·2025
Same author

Home Management of Refractory Ascites in Decompensated Cirrhosis With Long-Term Abdominal Drains, a Pilot Study.

JGH open : an open access journal of gastroenterology and hepatology·2025
Same author

Improving Neurosurgical Care in Egypt: A Questionnaire-Based Study of Neurosurgeons' and Patients' Perspectives on Risk Factors for Malpractice Claims.

World neurosurgery·2025

Related Experiment Video

Updated: Oct 18, 2025

A Protocol for Analyzing Hepatitis C Virus Replication
13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

24.4K

Treating chronic hepatitis C in general practice.

Kate Muller1, Mohamed Hasan2

  • 1MBBS, PhD, FRACP, Staff Specialist, Flinders Medical Centre, Bedford Park, SA; Senior Lecturer, Flinders University, Bedford Park, SA.

Australian Journal of General Practice
|September 30, 2021
PubMed
Summary

Hepatitis C virus (HCV) treatment is now achievable in general practice using safe and effective direct-acting antivirals (DAAs). This approach expands patient access and supports Australia

More Related Videos

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

2.4K
Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

7.0K

Related Experiment Videos

Last Updated: Oct 18, 2025

A Protocol for Analyzing Hepatitis C Virus Replication
13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

24.4K
A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

2.4K
Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

7.0K

Area of Science:

  • Hepatology
  • Virology
  • General Practice Medicine

Background:

  • Hepatitis C virus (HCV) infection remains a significant public health concern in Australia, contributing to considerable morbidity and mortality.
  • Many individuals remain unaware of their HCV infection, hindering eradication efforts.
  • The advent of direct-acting antivirals (DAAs) offers a paradigm shift, enabling higher viral eradication rates and improved treatment accessibility.

Purpose of the Study:

  • To provide guidance on the utilization of pan-genotypic direct-acting antivirals (DAAs) for Hepatitis C virus (HCV) treatment.
  • To outline criteria for referring patients to specialist care when necessary.

Main Methods:

  • This article focuses on the practical application of pan-genotypic DAAs in a general practice setting.
  • It emphasizes the safety and tolerability of current DAAs, facilitating their use by general practitioners.

Main Results:

  • General practice-based treatment of HCV with DAAs can significantly increase patient access to care.
  • This decentralized model reduces the burden on specialist services (gastroenterologists, hepatologists, infectious diseases physicians).

Conclusions:

  • Hepatitis C virus (HCV) treatment is feasible and highly effective in general practice using pan-genotypic DAAs.
  • Expanding treatment into primary care settings is crucial for advancing HCV eradication goals in Australia and preventing advanced liver disease.